The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
PPAR Agonists and Metabolic Syndrome: An Established Role?
Open accessAbstract
Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated receptors (PPARs) are involved in the metabolic regulation of lipid and lipoprotein levels, i.e., triglycerides (TGs), blood glucose, and abdominal adiposity. PPARs may be classified into the α, β/δ and γ subtypes. The PPAR-α agonists, mainly fibrates (including newer molecules such as pemafibrate) and omega-3 fatty acids, are powerful TG-lowering agents. They mainly affect TG catabolism and, particularly with fibrates, raise the levels of high-density lipoprotein cholesterol (HDL-C). PPAR-γ agonists, mainly glitazones, show a smaller activity on TGs but are powerful glucose-lowering agents. Newer PPAR-α/δ agonists, e.g., elafibranor, have been designed to achieve single drugs with TG-lowering and HDL-C-raising effects, in addition to the insulin-sensitizing and antihyperglycemic effects of glitazones. They also hold promise for the treatment of non-alcoholic fatty liver disease (NAFLD) which is closely associated with the MetS. The PPAR system thus offers an important hope in the management of atherogenic dyslipidemias, although concerns regarding potential adverse events such as the rise of plasma creatinine, gallstone formation, drug–drug interactions (i.e., gemfibrozil) and myopathy should also be acknowledged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107 · cited 1×
“While PPAR-γ is not needed for macrophage differentiation, it is fundamental for a proper anti-inflammatory activity in adipose tissue macrophages [54].”
Background(1999) · PubMed · Cited by 2,062
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamäki, J., Mykkänen, L., Kuusisto, J., Laakso, M., Fujimoto, W., & Auwerx, J. (1998) · Nature Genetics · doi:10.1038/3099 · Cited by 1,319
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Prevalence of the metabolic syndrome in the United States, 2003-2012
Aguilar, M., Bhuket, T., Torres, S., Liu, B., & Wong, R. J. (2015) · JAMA · doi:10.1001/jama.2015.4260 · Cited by 1,267
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
American College of Endocrinology Position Statement on the Insulin Resistance Syndrome
Einhorn, D. (2003) · Endocrine Practice · doi:10.4158/ep.9.s2.5 · Cited by 1,066
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00066-5 · Cited by 1,047
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
Acetyl-CoA and the regulation of metabolism: mechanisms and consequences
Shi, L., & Tu, B. P. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.003 · Cited by 903 · cited 1×
“, they, somewhat similar to drugs with a fatty acid-like structure, particularly fibrates, do not enter the liver metabolic handling by the classical fatty acetylCoA oxidative mechanism, with carnitine mediated transport to mitochondria [84].”
BackgroundChawla, A., Schwarz, E. J., Dimaculangan, D. D., & Lazar, M. A. (1994) · Endocrinology · doi:10.1210/en.135.2.798 · Cited by 873
Mechanisms of Action of (n-3) Fatty Acids,
Calder, P. C. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.155259 · Cited by 871
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale
Lefterova, M. I., Zhang, Y., Steger, D. J., Schupp, M., Schug, J., Cristancho, A., Feng, D., Zhuo, D., Stoeckert, C. J., Liu, X. S., et al. (2008) · Genes & Development · doi:10.1101/gad.1709008 · Cited by 824
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists
Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10843 · Cited by 537
The role of PPAR-γ in macrophage differentiation and cholesterol uptake
Moore, K. J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D., Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., & Freeman, M. W. (2001) · Nature Medicine · doi:10.1038/83328 · Cited by 513
Peroxisome proliferator‐activated receptor δ controls muscle development and oxydative capability
Luquet, S., Lopez‐Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M., & Grimaldi, P. A. (2003) · The FASEB Journal · doi:10.1096/fj.03-0269fje · Cited by 509
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., & Horikoshi, H. (1988) · Diabetes · doi:10.2337/diab.37.11.1549 · Cited by 473
Medical significance of peroxisome proliferator-activated receptors
Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 468
AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1
Lee, W. J., Kim, M., Park, H.-S., Kim, H. S., Jeon, M. J., Oh, K. S., Koh, E. H., Won, J. C., Kim, M.-S., Oh, G. T., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.011 · Cited by 420
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
PPARγ in adipocyte differentiation and metabolism – Novel insights from genome‐wide studies
Siersbæk, R., Nielsen, R., & Mandrup, S. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.010 · Cited by 400
Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency
Miles, P. D. G., Barak, Y., He, W., Evans, R. M., & Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8538 · Cited by 400
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Prevalence of metabolic syndrome in mainland china: a meta-analysis of published studies
Li, R., Li, W., Lun, Z., Zhang, H., Sun, Z., Kanu, J. S., Qiu, S., Cheng, Y., & Liu, Y. (2016) · BMC Public Health · doi:10.1186/s12889-016-2870-y · Cited by 369
Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes
Amri, E.-Z., Bonino, F., Ailhaud, G., Abumrad, N. A., & Grimaldi, P. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.5.2367 · Cited by 368
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008) · Diabetes · doi:10.2337/db07-1318 · Cited by 325
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284
Structure of HDL: Particle Subclasses and Molecular Components
Kontush, A., Lindahl, M., Lhomme, M., Calabresi, L., Chapman, M. J., & Davidson, W. S. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-09665-0_1 · Cited by 281
PPARγ signaling and emerging opportunities for improved therapeutics
Wang, S., Dougherty, E. J., & Danner, R. L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.028 · Cited by 248
Prevalence of metabolic syndrome in Brazilian adults: a systematic review
de Carvalho Vidigal, F., Bressan, J., Babio, N., & Salas-Salvadó, J. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-1198 · Cited by 246
Kastelein, J. J. P., Maki, K. C., Susekov, A., Ezhov, M., Nordestgaard, B. G., Machielse, B. N., Kling, D., & Davidson, M. H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.003 · Cited by 233
The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes
Quesada-López, T., Cereijo, R., Turatsinze, J.-V., Planavila, A., Cairó, M., Gavaldà-Navarro, A., Peyrou, M., Moure, R., Iglesias, R., Giralt, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13479 · Cited by 231
Kleemann, R., Gervois, P. P., Verschuren, L., Staels, B., Princen, H. M. G., & Kooistra, T. (2003) · Blood · doi:10.1182/blood-2002-06-1762 · Cited by 229
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227 · cited 1×
“PPAR agonists are generally recognized as effective pharmacological tools for the management of MetS [10,11].”
BackgroundPPARs Integrate the Mammalian Clock and Energy Metabolism
Chen, L., & Yang, G. (2014) · PPAR Research · doi:10.1155/2014/653017 · Cited by 222
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · cited 1×
“The role of fibrates in the clinical management of disorders characterized by elevated TGs is now well established [60].”
BackgroundLefterova, M. I., Steger, D. J., Zhuo, D., Qatanani, M., Mullican, S. E., Tuteja, G., Manduchi, E., Grant, G. R., & Lazar, M. A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01651-09 · Cited by 207
Wu, P., Peters, J. M., & Harris, R. A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5608 · Cited by 204
PPAR ? agonists stimulate oligodendrocyte differentiation in tissue culture
Saluja, I., Granneman, J. G., & Skoff, R. P. (2001) · Glia · doi:10.1002/1098-1136(200103)33:3<191::aid-glia1018>3.0.co;2-m · Cited by 200
Holst, D., Luquet, S., Nogueira, V., Kristiansen, K., Leverve, X., & Grimaldi, P. A. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00071-4 · Cited by 193
PPAR dual agonists: Are they opening Pandora's Box?
BALAKUMAR, P., ROSE, M., GANTI, S., KRISHAN, P., & SINGH, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 190
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 180
Self-citationFenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice
Oosterveer, M. H., Grefhorst, A., van Dijk, T. H., Havinga, R., Staels, B., Kuipers, F., Groen, A. K., & Reijngoud, D.-J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051052 · Cited by 174
Cariou, B., Zaïr, Y., Staels, B., & Bruckert, E. (2011) · Diabetes Care · doi:10.2337/dc11-0093 · Cited by 172
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164
Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells
Fan, Y., Wang, Y., Tang, Z., Zhang, H., Qin, X., Zhu, Y., Guan, Y., Wang, X., Staels, B., Chien, S., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.149815 · Cited by 163
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141 · cited 1×
“, TG reduction and HDL-C increment, in preclinical studies as well as in phase 1 and phase 2 clinical trials (previously reviewed [73,81]) led to the planning of the PROMINENT (pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes) trial (registered as NCT03071692).”
BackgroundArai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136
Saha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 129
Davidson, M., Meyer, P., Haffner, S. M., Feinstein, S. B., D’Agostino, R. B., Kondos, G. T., Pérez, A., Chen, Z., & Mazzone, T. (2008) · Circulation · doi:10.1161/circulationaha.107.746610 · Cited by 128
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.032 · Cited by 124
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124 · cited 1×
“9%, depending on fracture classification [125]; and (iii) a higher incidence of edema (+35.”
BackgroundThe Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A Review
Pizzini, A., Lunger, L., Demetz, E., Hilbe, R., Weiß, G., Ebenbichler, C. F., & Tancevski, I. (2017) · Nutrients · doi:10.3390/nu9101099 · Cited by 123
Molecular Mechanisms of PPAR-γ; Governing MSC Osteogenic and Adipogenic Differentiation
Zhuang, H., Zhang, X., Zhu, C., Tang, X., Yu, F., Shang, G., & Cai, X. (2016) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x10666150531173309 · Cited by 121
Jani, R. H., Pai, V., Jha, P. R., Jariwala, G., Mukhopadhyay, S., Bhansali, A. K., & Joshi, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 120
Nicholls, S. J., Tuzcu, E. M., Wolski, K., Bayturan, Ö., Lavoie, A., Uno, K., Kupfer, S., Pérez, A., Nesto, R. W., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.055 · Cited by 118
Huang, J., Jia, Y., Fu, T., Viswakarma, N., Bai, L., Rao, M. S., Zhu, Y., Borensztajn, J., & Reddy, J. K. (2011) · The FASEB Journal · doi:10.1096/fj.11-194019 · Cited by 116
PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders
Palomer, X., Barroso, E., Pizarro‐Delgado, J., Peña, L., Botteri, G., Zarei, M., Aguilar-Recarte, D., Montori-Grau, M., & Vázquez‐Carrera, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030913 · Cited by 116
Mice fed fish oil diet and upregulation of brown adipose tissue thermogenic markers
Bargut, T. C. L., da Silva-e-Silva, A. C. A. G., Souza‐Mello, V., Mandarim‐de‐Lacerda, C. A., & Águila, M. B. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0834-0 · Cited by 115
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 115
Stella, A. B., Cappellari, G. G., Barazzoni, R., & Zanetti, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010218 · Cited by 113
Omega-3 fatty acids and adipose tissue biology
Kuda, O., Rossmeisl, M., & Kopecký, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.01.004 · Cited by 112
Gray, E., Ginty, M., Kemp, K. C., Scolding, N. J., & Wilkins, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-63 · Cited by 106
Maki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.420 · Cited by 104 · cited 1×
“Phase 3 follow-up: 6 weeks subjects: 647 [108] 1.”
Hertz, R., Berman, I., KEPPLER, D. O. R., & Bar‐Tana, J. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00242.x · Cited by 104
Raza-Iqbal, S., Tanaka, T., Anai, M., Inagaki, T., Matsumura, Y., Ikeda, K., Taguchi, A., Gonzalez, F. J., Sakai, J., & Kodama, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.28720 · Cited by 100
Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-20 · Cited by 98
Ferri, N., & Ruscica, M. (2016) · Endocrine · doi:10.1007/s12020-016-0939-0 · Cited by 89
Self-citationPPARbeta/delta ligands as modulators of the inflammatory response.
Kilgore, K. S., & Billin, A. N. (2008) · PubMed · Cited by 87
Risk identification and possible countermeasures for muscle adverse effects during statin therapy
Magni, P., Macchi, C., Morlotti, B., Sirtori, C. R., & Ruscica, M. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.002 · Cited by 87
Self-citationZingarelli, B., Piraino, G., Hake, P. W., O’Connor, M. P., Denenberg, A. G., Fan, H., & Cook, J. A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091010 · Cited by 86
Peroxisome proliferator-activated receptors A link between endocrinology and nutrition?
Keller, H., & Wahli, W. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90048-j · Cited by 85
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 82
PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions
Wang, X., Wang, G., Shi, Y., Sun, L., Gorczynski, R. M., Li, Y., Xu, Z., & Spaner, D. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.41 · Cited by 82
Hill, M., Clarke, S. L., Rodgers, K., Thornhill, B., Peters, J. M., Gonzalez, F. J., & Gimble, J. M. (1999) · Infection and Immunity · doi:10.1128/iai.67.7.3488-3493.1999 · Cited by 81
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80 · cited 1×
“Apparently, products containing DHA may increase LDL-C levels, whereas those containing EPA only products do not lead to a similar consequence [104,105].”
BackgroundExamining the safety of PPAR agonists – current trends and future prospects
Bortolini, M., Wright, M. B., Bopst, M., & Balas, B. I. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.741585 · Cited by 77
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
Inzucchi, S. E., Viscoli, C. M., Young, L. H., Furie, K. L., Gorman, M., Lovejoy, A. M., Dagogo-Jack, S. E., Ismail‐Beigi, F., Korytkowski, M. T., Pratley, R. E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0798 · Cited by 77
Elevated concentrations of plasma ω-3 polyunsaturated fatty acids among Alaskan Eskimos
Parkinson, A. J., Cruz, A., Heyward, W., BULKOW, L. R., Hall, D., Barstaed, L., & We, C. (1994) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/59.2.384 · Cited by 76
Pharmacokinetic Interactions Between Statins and Fibrates
Corsini, A., Bellosta, S., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.007 · Cited by 69
Ruscica, M., Baragetti, A., Catapano, A. L., & Norata, G. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.12.005 · Cited by 69
Self-citationCermenati, G., Audano, M., Giatti, S., Carozzi, V., Porretta‐Serapiglia, C., Pettinato, E., Ferri, C., D’Antonio, M., Fabiani, E. D., Crestani, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.016 · Cited by 64
Self-citationPPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 63
Self-citationForyst‐Ludwig, A., Hartge, M., Clemenz, M., Sprang, C., Heß, K., Marx, N., Unger, T., & Kintscher, U. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-64 · Cited by 57
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 57
Self-citationPemafibrate: First Global Approval
Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0818-x · Cited by 54
Pahlavani, M., Ramalho, T. R. D. O., Koboziev, I., LeMieux, M. J., Jayarathne, S., Ramalingam, L., Filgueiras, L. R., & Moustaïd‐Moussa, N. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000535 · Cited by 54
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Monk, J. M., Liddle, D. M., Boer, A. A. D., Brown, M. J., Power, K. A., David, W. L., & Robinson, L. E. (2015) · Journal of Nutrition · doi:10.3945/jn.114.205443 · Cited by 51
Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
Pirillo, A., & Catapano, A. L. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.040 · Cited by 50
Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx659 · Cited by 47
Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids
Burke, M. F., Burke, F. M., & Soffer, D. E. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0700-z · Cited by 44
Chatterjee, S., Majumder, A., & Ray, S. (2015) · Scientific Reports · doi:10.1038/srep07706 · Cited by 42
Stroes, E. S. G., Susekov, A. V., de Bruin, T. W. A., Kvarnström, M., Yang, H., & Davidson, M. H. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.012 · Cited by 38
Nutraceutical approaches to metabolic syndrome
Sirtori, C. R., Pavanello, C., Calabresi, L., & Ruscica, M. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1366042 · Cited by 37
Self-citationUpdate on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3
Catapano, A. L., & Pirillo, A. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s67551 · Cited by 36
Antidiabetic Action of Bezafibrate in a Large Observational Database
Flory, J., Ellenberg, S. S., Szapary, P. O., Strom, B. L., & Hennessy, S. (2009) · Diabetes Care · doi:10.2337/dc08-1809 · Cited by 36
Simental‐Mendía, L. E., Simental-Mendía, M. A., Sánchez‐García, A., Banach, M., Atkin, S. L., Gotto, A. M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.030 · Cited by 36
Self-citationHistory and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., & Mitro, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.005 · Cited by 32
Self-citationFraudulent (and non fraudulent) fatty acids for human health
Sirtori, C. R., Galli, C., & Franceschini, G. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb01286.x · Cited by 29
Self-citationIs It Time for New Thinking About High-Density Lipoprotein?
Madsen, C. M., & Nordestgaard, B. G. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310727 · Cited by 29
Keech, A., & Field Study Investigators (2006) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(06)81349-8 · Cited by 28
CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone
Betteridge, D. J. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00741.x · Cited by 28
Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25
Self-citationGPR120 in adipocytes has differential roles in the production of pro-inflammatory adipocytokines
Hasan, A. U., Ohmori, K., Hashimoto, T., Kamitori, K., Yamaguchi, F., Noma, T., Igarashi, J., Tsuboi, K., Tokuda, M., Nishiyama, A., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.001 · Cited by 23
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., Doyle, R. T., Philip, S., Soni, P. N., & Juliano, R. A. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0137 · Cited by 22
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Nikolić, D., Castellino, G., Banach, M., Toth, P. P., Ivanova, E. A., Orekhov, A. N., Montalto, G., & Rizzo, M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666161006151134 · Cited by 21
Brown but not white adipose cells synthesize omega-3 docosahexaenoic acid in culture
Qin, X., Park, H. G., Zhang, J. Y., Lawrence, P., Liu, G., Subramanian, N., Kothapalli, K. S. D., & Brenna, J. T. (2015) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.11.001 · Cited by 15
Camejo, G. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.013 · Cited by 11
Sirtori, C. R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68500-0 · Cited by 6
Self-citationMechanisms of Action of Absorbable Hypolipidemic Drugs
Sirtori, C. R. (1985) · Springer eBooks · doi:10.1007/978-1-4613-2459-1_19 · Cited by 5
Self-citation
Research works printed but not linked: 1
- Motoki, 2015, PPAR-gamma agonist attenuates inflammation in aortic aneurysm patients, Gen. Thorac. Cardiovasc. Surg., 63, 565, 10.1007/s11748-015-0576-1 · doi:10.1007/s11748-015-0576-1
Cited by
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Brase, R. A., Mullin, E. J., & Spink, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22030995 · Cited by 374
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
Metadata
- Authors
- Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-04-14
- Volume
- 19
- Issue
- 4
- Pages
- 1197
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2797947316
- Cited by
- 253
- References
- 142
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Fondazione Cariplo grant (2015-0552)
- Linea 2, Azione (Intramural grant) received by Università degli Studi di Milano
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.